2076975 2077203
최종편집 2024-05-27 07:58 (월)
Korean top drug makers’ Q2 earnings consensus, sales – operating profit mismatch
상태바
Korean top drug makers’ Q2 earnings consensus, sales – operating profit mismatch
  • Hyeokgi Lee, Newsmp
  • 승인 2022.07.26 18:10
  • 댓글 0
이 기사를 공유합니다

GC PharmaㆍChong Kun Dang PharmaceuticalㆍDong-A ST, sales above consensus… Only Daewoong Pharmaceutical’s operating profit rose

[Newsmp] Stock market consensus toward major top pharmaceutical companies is fluctuating ahead of the Q2 earnings announcement.

While Hanmi Pharmaceutical earlier released its report that greatly exceeds the consensus as if it protested the negative gaze of the stock market, the consensus of other top companies has not been established since then.

Over the past week, the sales consensus of three major drug makers, GC Pharma, Chong Kun Dang Pharmaceutical, and Dong-A ST, rose, while their operating profit consensus fell.

On the contrary, Daewoong Pharmaceutical’s sales consensus declined, while its operating profit consensus gained.

Among them, GC Pharma’s sales and operating profit consensus have fallen recently, but its sales consensus has risen slightly to KRW 420 billion over the past week.

However, its operating profit consensus, which exceeded KRW 17 billion a month ago, has reduced below KRW 15 billion.

Chong Kun Dang Pharmaceutical’s sales consensus, which had been continuously falling, also rose slightly to KRW 353.2 billion, a little higher than a month ago.

Nevertheless, its operating profit consensus, which exceed KRW 30 billion three months ago, has been pushed back to KRW 26 billion.

Dong-A ST’s sales consensus, which had been pegged at KRW 156.8 billion, advanced to KRW 158 billion, but the operating profit consensus dropped to KRW 5 billion from KRW 6 billion.

Unlike Dong-A ST, Daewoong Pharmaceutical’s sales consensus fell to KRW 308 billion from KRW 309 billion.

On the other hand, the operating profit consensus, which fell from the KRW 25 billion mark three months ago to the KRW 22 billion mark a month ago, has steadily risen since then, and recently expanded to KRW 25.7 billion, higher than three months ago.

Unlike the contrary trend of sales and operating profit consensus of major top pharmaceutical companies, Yuhan Corporation continues to decrease both indicators.

In the past month, Yuhan's sales consensus fell from the 470 billion mark to KRW 460 billion mark, and operating profit shrank from KRW 19 billion mark to KRW 16.6 billion.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.